Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology

Jubilant Therapeutics is preparing for Phase II and first-in-human trials later in 2023, with two Orphan Drug Designations, an advantageous safety profile and enhanced therapeutic indices. The company's pipeline is generated 100% in-house using its Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, which permits the identification of candidate molecules with enhanced the..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 20.
  • textsms

MindRank Announces First-in-Human Phase 1 Study of MDR-001 in China

Clinical stage AI drug discovery company, MindRank, has announced the start of its first-in-human (FIH) Phase 1 study of MDR-001 in China. The proprietary glucagon-like peptide 1 receptor agonist (GLP-1 RA), which is an oral small-molecule designed to treat obesity and type 2 diabetes mellitus (T2DM), was discovered using MindRank's Molecule Pro AI platform. The FIH Phase 1 trial will evaluate t..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 15.
  • textsms